Nasdaq:US$17.92 (-0.64) | HKEX:HK$28.60 (-0.75) | AIM:£2.79 (-0.11)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors